SCHEMBL5140283

SCHEMBL5140283

C=CC(C(=O)C(C=C)c1ccc(N2CCOCC2)cc1)c1ccc(N2CCOCC2)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.46
LMNA P02545 1/20 0.46
GSK3B P49841 1/20 0.45
PRKDC P78527 2/20 0.43
PIK3CD O00329 1/20 0.43
PIK3CA P42336 1/20 0.43
PIK3CB P42338 1/20 0.43
PIK3CG P48736 1/20 0.43
MAPT P10636 3/20 0.43
MEN1 O00255 3/20 0.43
KMT2A Q03164 3/20 0.43
NPC1 O15118 3/20 0.43
RAB9A P51151 3/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
MAOB P27338 1/20 0.43
HIF1A Q16665 1/20 0.42
KDM4E B2RXH2 1/20 0.41
HPGD P15428 1/20 0.41
ALOX15 P16050 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5140282 0.76 PIK3CD (0.44) ALDH1A1LMNAGSK3BPRKDCPIK3CD
SCHEMBL27536636 0.76 ALDH1A1 (0.56) ALDH1A1LMNAGSK3BPRKDCMAPT
SCHEMBL11951500 0.72 MAOB (0.60) ALDH1A1LMNAGSK3BMAPTMEN1
SCHEMBL23053215 0.72 ALDH1A1 (0.49) ALDH1A1LMNAGSK3BPRKDCMAPT
SCHEMBL11061699 0.72 ALDH1A1 (0.49) ALDH1A1LMNAGSK3BPRKDCMAPT
SCHEMBL3158614 0.72 LMNA (0.52) ALDH1A1LMNAGSK3BPRKDCPIK3CD
SCHEMBL18212293 0.72 LMNA (0.52) ALDH1A1LMNAGSK3BPRKDCPIK3CD
SCHEMBL27811257 0.72 GSK3B (0.56) ALDH1A1LMNAGSK3BPRKDCMAPT
SCHEMBL6383636 0.71 ALDH1A1 (0.50) ALDH1A1LMNAGSK3BPRKDCPIK3CD
SCHEMBL5217443 0.71 ALDH1A1 (0.55) ALDH1A1LMNAGSK3BPRKDCMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080045708-A1 New Process for the Synthesis of Morpholinylbenzenes TIAN WEI 2008-02-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080045708-A1 New Process for the Synthesis of Morpholinylbenzenes CYP1B1, TBCB, MAP1B ALDH1A1 2203/4885LMNA 1456/4885GSK3B 3241/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.